Medical blog

Approximately 120 million thyroid-related lab tests are performed in
the United States each year. At an estimated average cost of $40 per
test, the U.S. market is currently valued at nearly $5 billion.
Approximately 45 million of those tests are conducted in order to
diagnose thyroid dysfunction. CLX believes that ThyroTest(R) is an
appropriate, cost-effective first-step for those 45 million diagnostic
TSH tests. This current U.S. market opportunity is amplified by the
CLIA waived status, which makes the opportunity to meet American
Thyroid Association recommendations for screening every individual at
age 35 and every five years thereafter a reality.